89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo

Conclusion: This study shows that nonspecific uptake of mAbs for tissues without target expression can be quantified using 89Zr-immuno-PET at multiple time points. These results form a crucial base for measurement of target engagement by therapeutic antibodies in vivo with 89Zr-immuno-PET. For future studies, a pilot phase including at least 3 scans at 1 or more days after injection is required to assess nonspecific uptake as a function of time, to optimize study design for detection of target engagement.

Source: Journal of Nuclear Medicine - December 1, 2019 Category: Nuclear Medicine Authors: Jauw, Y. W. S., ODonoghue, J. A., Zijlstra, J. M., Hoekstra, O. S., Menke-van der Houven van Oordt, C. W., Morschhauser, F., Carrasquillo, J. A., Zweegman, S., Pandit-Taskar, N., Lammertsma, A. A., van Dongen, G. A. M. S., Boellaard, R., Weber, W. A., Hui Tags: Translational Source Type: research